SHR 0410
Alternative Names: SHR-0410Latest Information Update: 28 May 2024
Price :
$50 *
At a glance
- Originator Atridia
- Class Analgesics; Antipruritics
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Postoperative pain
- No development reported Acute pain; Pruritus
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Acute pain(In volunteers) in Australia (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Pruritus in Australia (IV, Injection)
- 28 May 2024 No recent reports of development identified for phase-I development in Pruritus in China (IV, Injection)